术前新辅助化疗结合PD-1抑制剂对三阴性乳腺癌患者术后恢复情况的影响  

Effect of Preoperative Neoadjuvant Chemotherapy Combined with PD-1 Inhibitors on Postoperative Recovery in Patients with Triple Negative Breast Cancer

作　　者：朱宝平[1] 陈明 ZHU Baoping;CHEN Ming(Department of General Surgery,Shouguang People’s Hospital,Weifang 261000,China)

机构地区：[1]山东省寿光市人民医院普外科,山东潍坊261000

出　　处：《中国伤残医学》2025年第7期37-41,共5页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:分析术前新辅助化疗结合程序性细胞死亡蛋白-1(PD-1)抑制剂对三阴性乳腺癌患者术后恢复情况的影响。方法:选取2021年2月—2022年9月寿光市人民医院收治的86例三阴性乳腺癌患者为研究对象,采用随机数字表法将其分为对照组和研究组,各43例。所有患者均行手术治疗。术前,对照组采用新辅助化疗治疗,研究组采用新辅助化疗结合PD-1抑制剂治疗。比较两组治疗效果、术中出血量、手术时间、免疫功能指标、术后病理分级、生活质量。结果:对照组治疗总有效率为72.09%,低于研究组的90.70%,差异有统计学意义(P<0.05)。对照组术中出血量多于研究组,手术时间长于研究组,差异均有统计学意义(P<0.05)。治疗后,对照组CD4^(+)、CD8^(+)及CD4^(+)/CD8^(+)水平均低于研究组,差异均有统计学意义(P<0.05)。研究组术后病理分级优于对照组,差异有统计学意义(P<0.05)。治疗后,两组健康调查简表中各个维度评分均高于治疗前,且对照组低于研究组,差异均有统计学意义(P<0.05)。结论:对需要术前化疗的三阴性乳腺癌患者,采用新辅助化疗与PD-1抑制剂共同治疗,效果理想,利于手术实施,提升生活质量及免疫功能,改善病理分级。Objective:To analyze the effect of preoperative neoadjuvant chemotherapy combined with programmed cell death protein-1(PD-1)inhibitor on postoperative recovery of patients with triple negative breast cancer.Methods:A total of 86 patients with triplenegative breast cancer treated in Shouguang People’s Hospital from February 2021 to September 2022 were selected as the study objects,and were divided into a control group and a study group by random number table method,with 43 cases in each group.All patients underwent surgery.Before surgery,the control group was treated with neoadjuvant chemotherapy,and the study group was treated with neoadjuvant chemotherapy combined with PD-1 inhibitor.The therapeutic effect,intraoperative blood loss,operative time,immune function index,postoperative pathological grade and quality of life were compared between the two groups.Results:The total effective rate of the control group was 72.09%,which was lower than 90.70%of the study group,the difference was statistically significant(P<0.05).The amount of blood loss during operation in the control group was higher than that in the study group,and the operation time was longer than that in the study group,with statistical significance(P<0.05).After treatment,the levels of CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)in the control group were lower than those in the study group,with statistical significance(P<0.05).The postoperative pathological grade of the study group was better than that of the control group,the differences was statistically significant(P<0.05).After treatment,the scores of all dimensions of the MOS Item Short Form Health Survey in both groups were higher than before treatment,and the control group was lower than the study group,with statistical significance(P<0.05).Conclusion:For triplenegative breast cancer patients who need preoperative chemotherapy,neoadjuvant chemotherapy combined with PD-1 inhibitor has ideal effect,which is conducive to operation,improvement of quality of life and immune function,and improvement of patho

关 键 词：三阴性乳腺癌 程序性细胞死亡蛋白-1抑制剂 新辅助化疗 术后病理分级 生活质量 

分 类 号：R445[医药卫生—影像医学与核医学]